370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial

• Ana Oaknin,
• Maria-Pilar Barretina-Ginesta,
• Victor Moreno,
• Thierry André,
• Ruth Plummer,
• Florence Joly,
• Rowan Miller,
• Joanna Pikiel,
• Susana Banerjee,
• Jose Manuel Trigo Perez,
• Bhavana Pothuri,
• Andrea Jewell,
• Anna Tinker,
• Dominique Berton,
• Susan Ellard,
• Jennifer Veneris,
• Tao Duan

Affiliations

Ana Oaknin

Vall d`Hebron University Hospital, Barcelona, Catalunya, Spain

Maria-Pilar Barretina-Ginesta

4 Medical Oncology Department, Catalan Institute of Oncology, Hospital Universitari Dr Josep Trueta, Girona, Spain

Victor Moreno

Cancer Prevention and Control Program, Catalan Institute of Oncology - IDIBELL, L`Hospitalet de Llobregat, Barcelona, Spain

Thierry André

Sorbonne Université and Hospital Saint Antoine, Department of Medical Oncology, AP-HP, Paris, France

Ruth Plummer

Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust and Newcastle University, Newcastle upon Tyne, UK

Florence Joly

5 GINECO and Regional Centre Control Against Cancer Francois, Baclesse Caen, France

Rowan Miller

4 Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK

Joanna Pikiel

29 Department of Oncology, Wojewodzkie Centrum Oncologii, Gdańsk, Poland

Susana Banerjee

Gynaecology Unit, Royal Marsden NHS Foundation Trust, London, UK

Jose Manuel Trigo Perez

6Hospital Virgen de la Victoria, Málaga, Spain

Bhavana Pothuri

9New York University; Department of Obstetrics and Gynecology

Andrea Jewell

Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS.

Anna Tinker

NCIC-CTG, Canada;

Dominique Berton

1GINECO and Institut de Cancérologie de l’Ouest (ICO), Centre René Gauducheau, Saint-Herblain, France

Susan Ellard

7BC Cancer-Kelowna, British Columbia, Canada

Jennifer Veneris

16GlaxoSmithKline, London, UK

Tao Duan

16GlaxoSmithKline, London, UK